Nialamid

Nialamid
(IUPAC) ime
	N-benzil-3-(N'-(piridin-4-karbonil)hidrazino)propanamid
Klinički podaci
AHFS/Drugs.com	Internacionalno ime leka
Identifikatori
CAS broj	51-12-7
ATC kod	N06AF02
PubChem	4472
DrugBank	DB04820
ChemSpider	4317
UNII	T2Q0RYM725
KEGG	D07337
Hemijski podaci
Formula	C16H18N4O2
Mol. masa	298,34 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C16H18N4O2/c21-15(18-12-13-4-2-1-3-5-13)8-11-19-20-16(22)14-6-9-17-10-7-14/h1-7,9-10,19H,8,11-12H2,(H,18,21)(H,20,22) ; Key: NOIIUHRQUVNIDD-UHFFFAOYSA-N
Farmakoinformacioni podaci
Trudnoća	?
Pravni status	Samo na recept (S4) (AU)
Način primene	Oralno

Nialamid (Niamid) ireverzibilni i neselektivni je inhibitor monoaminske oksidaze (MAOI) iz hidrazinske hemijske klase, koji je korišten kao antidepresiv i anksiolitik.

Potencijalne primene

Nialamid se ponekad koristi za tretman trigeminalne neuralgije, geleralizovanog anksioznog poremećaja i socijalne fobije. On je takođe izučavan za moguću primenu u tretmanu alkoholizma,^[5] iregularne menstruacije,^[6] angine,^[7] cerebrovaskularnih poremećaja,^[8] i za prevenciju streptomicinom indukovane gluvoće.^[9]

Reference

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.
↑ Bobrov AE, Shurygin AN, Krasil'nikov SB (1991). „[Effectiveness of combined use of monoamine oxidase inhibitors and psychotherapy in the treatment of chronic alcoholism]”. Zhurnal Nevropatologii i Psikhiatrii Imeni SS Korsakova. 91 (2): 79–83. PMID 1647635.
↑ Gautray JP, Jolivet A (1976). „[Neuroendocrine investigation and therapy of the menstrual ćcle disorders (author's transl)(proceedings)]”. Annales d'endocrinologie 37 (4): 293–4. PMID 1022189.
↑ Barats SS, Oranskii IE, Kartashova DI, Gorovater EN (1976). „[Comparative clinico-physiological stuđ of the effect of several MAO inhibitors in stenocardia]”. Kardiologiia 16 (3): 138–40. PMID 1021625.
↑ Mirzoian RS (1975). „[Prevention of cerebrovascular disorders with adrenergic substances]”. Biulleten' Eksperimental'noi Biologii i Meditsinj 80 (11): 50–3. PMID 1218262.
↑ Semczuk B, Klonowski S, Golabek W (1974). „The protective effect of niamid on hearing in patients treated with large doses of streptomycin”. Annales Universitatis Mariae Curie-Sklodowska Sectio D: Medicina 29 (1): 193–7. PMID 4467804.

Povezano

Hidrazin (antidepresiv)

Spoljašnje veze

	Portal Medicina
	Portal Hemija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit

[4] Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.

[Bobrov_et_al_1991-5] Bobrov AE, Shurygin AN, Krasil'nikov SB (1991). „[Effectiveness of combined use of monoamine oxidase inhibitors and psychotherapy in the treatment of chronic alcoholism]”. Zhurnal Nevropatologii i Psikhiatrii Imeni SS Korsakova. 91 (2): 79–83. PMID 1647635.

[Gautray_et_al_1976-6] Gautray JP, Jolivet A (1976). „[Neuroendocrine investigation and therapy of the menstrual ćcle disorders (author's transl)(proceedings)]”. Annales d'endocrinologie 37 (4): 293–4. PMID 1022189.

[Barats_et_al_1976-7] Barats SS, Oranskii IE, Kartashova DI, Gorovater EN (1976). „[Comparative clinico-physiological stuđ of the effect of several MAO inhibitors in stenocardia]”. Kardiologiia 16 (3): 138–40. PMID 1021625.

[Mirzoian_1975-8] Mirzoian RS (1975). „[Prevention of cerebrovascular disorders with adrenergic substances]”. Biulleten' Eksperimental'noi Biologii i Meditsinj 80 (11): 50–3. PMID 1218262.

[Semczuk_et_al_1974-9] Semczuk B, Klonowski S, Golabek W (1974). „The protective effect of niamid on hearing in patients treated with large doses of streptomycin”. Annales Universitatis Mariae Curie-Sklodowska Sectio D: Medicina 29 (1): 193–7. PMID 4467804.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]